(Q37534725)

20 August 2017

1 reference

title

The search for new COX-2 inhibitors: a review of 2002 - 2008 patents (English)

1 reference

20 August 2017

0 references

Matheus P Freitas

4

0 references

Teodorico C Ramalho

object named as

Teodorico C Ramalho

series ordinal

1

0 references

author name string

Marcus V J Rocha

series ordinal

2

1 reference

20 August 2017

Elaine F F da Cunha

series ordinal

3

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Expert Opinion on Therapeutic Patents

20 August 2017

published in

1 reference

20 August 2017

volume

19

1 reference

20 August 2017

issue

9

1 reference

20 August 2017

page(s)

1193-1228

1 reference

Tetra substituted thiophenes as anti-inflammatory agents: exploitation of analogue-based drug design

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

COX-2 selective inhibitors: a literature review of analgesic efficacy and safety in oral-maxillofacial surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Effects of cyclooxygenase inhibition on the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Pharmacodynamic of cyclooxygenase inhibitors in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Evaluation of intravenous parecoxib for the relief of acute post-surgical pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Lumiracoxib in the management of osteoarthritis and acute pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

The effects of epidural deracoxib on the ground reaction forces in an acute stifle synovitis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Clinical pharmacology of novel selective COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Comparison of Hydroperoxide Initiator Requirements for the Cyclooxygenase Activities of Prostaglandin H Synthase-1 and −2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Coupling between cyclooxygenase, terminal prostanoid synthase, and phospholipase A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3'-untranslated region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Design, synthesis, and biological evaluation of (E)-3-(4-methanesulfonylphenyl)-2-(aryl)acrylic acids as dual inhibitors of cyclooxygenases and lipoxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Evaluation of 2 celecoxib derivatives: analgesic effect and selectivity to cyclooxygenase-2/1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Inhibitory mode of 1,5-diarylpyrazole derivatives against cyclooxygenase-2 and cyclooxygenase-1: molecular docking and 3D QSAR analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Synthesis and SAR/3D-QSAR studies on the COX-2 inhibitory activity of 1,5-diarylpyrazoles to validate the modified pharmacophore

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

A comparison of the cyclooxygenase inhibitor-NO donors (CINOD), NMI-1182 and AZD3582, using in vitro biochemical and pharmacological methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

The cyclooxygenase-2 inhibitor GW406381X [2-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-pyrazolo[1,5-b]pyridazine] is effective in animal models of neuropathic pain and central sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Design, synthesis, and biological evaluation of substituted 3-alkylthio-4,5-diaryl-4H-1,2,4-triazoles as selective COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Studies of eicosanoid production in the air pouch model of synovial inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Synthesis of 4-(5-[18F]fluoromethyl-3-phenylisoxazol-4-yl)benzenesulfonamide, a new [18F]fluorinated analogue of valdecoxib, as a potential radiotracer for imaging cyclooxygenase-2 with positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Synthesis, in vitro, and in vivo biological evaluation and molecular docking simulations of chiral alcohol and ether derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Synthesis, biological evaluation, and enzyme docking simulations of 1,5-diarylpyrrole-3-alkoxyethyl ethers as selective cyclooxygenase-2 inhibitors endowed with anti-inflammatory and antinociceptive activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Recent new approaches to the treatment of head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

COX-2 inhibition: a possible role in the management of prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

New approaches to the modulation of the cyclooxygenase-2 and 5-lipoxygenase pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

21 January 2018

The Protein Data Bank

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Structural insights into the stereochemistry of the cyclooxygenase reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

5-heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part 1: Structure-activity relationship studies of 5-alkylamino pyrazoles and discovery of a potent, selective, and orally active analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Synthesis and selective cyclooxygenase-2 (COX-2) inhibitory activity of a series of novel bicyclic pyrazoles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Design, synthesis, and biological evaluation of N-acetyl-2-carboxybenzenesulfonamides: a novel class of cyclooxygenase-2 (COX-2) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Novel anti-inflammatory agents based on pyridazinone scaffold; design, synthesis and in vivo activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Current status of COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Synthesis and cyclooxygenase inhibitory activities of linear 1-(methanesulfonylphenyl or benzenesulfonamido)-2-(pyridyl)acetylene regioisomers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

Interactions of 5-deazapteridine derivatives with Mycobacterium tuberculosis and with human dihydrofolate reductases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

The search for new DHFR inhibitors: a review of patents, January 2001 – February 2005

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903059125

10.1517/13543770903059125

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference